IN2014DN09326A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09326A
IN2014DN09326A IN9326DEN2014A IN2014DN09326A IN 2014DN09326 A IN2014DN09326 A IN 2014DN09326A IN 9326DEN2014 A IN9326DEN2014 A IN 9326DEN2014A IN 2014DN09326 A IN2014DN09326 A IN 2014DN09326A
Authority
IN
India
Prior art keywords
blepharitis
fluticasone
triamcinolone
asthma
topical
Prior art date
Application number
Other languages
English (en)
Inventor
Thomas Cavanagh
Shikha P Barman
Tian Hao
Thomas B Leland
Ritesh V Thekkedath
Original Assignee
Aciex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/735,973 external-priority patent/US8765725B2/en
Application filed by Aciex Therapeutics Inc filed Critical Aciex Therapeutics Inc
Publication of IN2014DN09326A publication Critical patent/IN2014DN09326A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/0026Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN9326DEN2014 2012-05-08 2013-05-06 IN2014DN09326A (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261644105P 2012-05-08 2012-05-08
US201261657239P 2012-06-08 2012-06-08
US201261692487P 2012-08-23 2012-08-23
US13/735,973 US8765725B2 (en) 2012-05-08 2013-01-07 Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US201361763770P 2013-02-12 2013-02-12
US201361788519P 2013-03-15 2013-03-15
PCT/US2013/039694 WO2013169647A1 (fr) 2012-05-08 2013-05-06 Préparations d'agents thérapeutiques hydrophobes, procédés de fabrication et utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
IN2014DN09326A true IN2014DN09326A (fr) 2015-07-10

Family

ID=49551187

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9326DEN2014 IN2014DN09326A (fr) 2012-05-08 2013-05-06

Country Status (19)

Country Link
US (3) US10174071B2 (fr)
EP (3) EP2847207B1 (fr)
JP (4) JP6285419B2 (fr)
KR (1) KR102129426B1 (fr)
CN (2) CN104350063B (fr)
AU (1) AU2013259872B2 (fr)
BR (1) BR112014027681B8 (fr)
CA (1) CA2872845C (fr)
DK (1) DK3517541T3 (fr)
ES (2) ES2813397T3 (fr)
HK (2) HK1207087A1 (fr)
HU (1) HUE050993T2 (fr)
IN (1) IN2014DN09326A (fr)
MX (1) MX361886B (fr)
PL (1) PL3517541T3 (fr)
PT (1) PT3517541T (fr)
RU (1) RU2663117C2 (fr)
WO (1) WO2013169647A1 (fr)
ZA (1) ZA201408119B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3010628B1 (fr) 2013-09-18 2015-10-16 Medicrea International Procede permettant de realiser la courbure ideale d'une tige d'un materiel d'osteosynthese vertebrale destinee a etayer la colonne vertebrale d'un patient
FR3012030B1 (fr) 2013-10-18 2015-12-25 Medicrea International Procede permettant de realiser la courbure ideale d'une tige d'un materiel d'osteosynthese vertebrale destinee a etayer la colonne vertebrale d'un patient
WO2015126944A1 (fr) 2014-02-18 2015-08-27 Henkin Robert I Procédés et compositions permettant de diagnostiquer et de traiter une perte et/ou une distorsion du goût ou de l'odorat
CN106459137B (zh) * 2014-05-01 2019-04-12 整体生物系统有限责任公司 用于治疗眼部病症的膜附着性自组装体系
CN107427464B (zh) 2015-01-26 2022-04-05 博士伦公司 眼用悬浮液组合物
JP2017059651A (ja) 2015-09-16 2017-03-23 株式会社東芝 光電変換材料分散液とその製造方法、光電変換膜の製造方法と製造装置、および光電変換素子
WO2017221314A1 (fr) * 2016-06-20 2017-12-28 エム・テクニック株式会社 Procédé pour produire des particules fines organiques.
WO2018109556A1 (fr) 2016-12-12 2018-06-21 Medicrea International Systèmes et procédés pour des implants rachidiens spécifiques au patient
EP4108201B1 (fr) 2017-04-21 2024-03-27 Medicrea International Système permettant de développer un ou plusieurs implants rachidiens spécifiques au patient
AU2018318123A1 (en) 2017-08-15 2020-03-19 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
US10918422B2 (en) 2017-12-01 2021-02-16 Medicrea International Method and apparatus for inhibiting proximal junctional failure
JP7332602B2 (ja) * 2017-12-28 2023-08-23 センジュ ユーエスエー、インコーポレイテッド 経皮薬物送達システムおよびその使用方法
CN108815129A (zh) * 2018-07-12 2018-11-16 天津双硕医药科技有限公司 一种恩杂鲁胺纳米晶体口服固体药物组合物
CN108853017B (zh) * 2018-09-17 2021-03-02 西安力邦医药科技有限责任公司 一种雌三醇纳米口服制剂的组方与制备工艺
WO2020201353A1 (fr) 2019-04-02 2020-10-08 Medicrea International Systèmes, procédés et dispositifs pour développer des implants spinaux spécifiques d'un patient, des traitements, des opérations et/ou des procédures
US11925417B2 (en) 2019-04-02 2024-03-12 Medicrea International Systems, methods, and devices for developing patient-specific spinal implants, treatments, operations, and/or procedures
EP3955934A4 (fr) * 2019-04-16 2022-12-14 Clearside Biomedical, Inc. Formulations injectables de triamcinolone
PT3769753T (pt) 2019-07-23 2022-02-15 Nicox Ophthalmics Inc Processo para a preparação de suspensões aquosas oftálmicas estéreis de nanocristais de forma a de propianato de fluticasona
US11769251B2 (en) 2019-12-26 2023-09-26 Medicrea International Systems and methods for medical image analysis
JP2020107912A (ja) * 2020-04-06 2020-07-09 株式会社東芝 光電変換膜の製造方法と光電変換素子の製造方法
WO2021258326A1 (fr) * 2020-06-24 2021-12-30 中国人民解放军军事科学院军事医学研究院 Application de nanocristaux de midazolam dans la préparation d'un médicament destiné à améliorer la perméabilité de la barrière hémato-encéphalique
KR102229716B1 (ko) * 2020-10-14 2021-03-18 주식회사 판촉사랑 목걸이형 마스크
KR102326648B1 (ko) * 2020-12-04 2021-11-17 주식회사 피씨이노베이션 걸이끈이 구비된 마스크
CN115192524B (zh) * 2021-04-13 2023-08-29 杭州汉菁生物科技有限公司 一种包载链状难溶药物的聚合型胶束及制备方法和应用
JPWO2023038114A1 (fr) * 2021-09-10 2023-03-16
WO2023122469A2 (fr) * 2021-12-21 2023-06-29 Cyrano Therapeutics, Inc. Implants pour perte de goût et d'odeur
WO2023183603A1 (fr) * 2022-03-24 2023-09-28 Taro Pharmaceutical Industries Ltd. Utilisation topique de terbinafine et de composés similaires pour traiter des affections oculaires inflammatoires
WO2024118330A1 (fr) * 2022-11-29 2024-06-06 Corning Incorporated Solutions aqueuses pour le nettoyage d'articles en verre et procédés d'utilisation de celles-ci
CN115804756B (zh) * 2022-12-28 2024-04-05 山东中医药大学附属医院 超临界流体制备奥硝唑脂质体及其制剂

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1291A (en) 1980-02-15 1985-10-18 Glaxo Group Ltd Androstane 17 beta carbothioates
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US6486274B1 (en) 1997-01-28 2002-11-26 Fina Technology, Inc. Hydrogen response Ziegler-Natta catalyst for narrowing MWD of polyolefin, method of making, method of using, and polyolefins made therewith
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
CA2289618A1 (fr) * 1997-05-14 1998-11-19 Shin-Ichi Yasueda Preparations a base de suspensions aqueuses possedant d'excellentes proprietes de redispersion
DE19724397A1 (de) 1997-06-10 1999-01-14 Bayer Ag UV-Stabilisatoren für Siloxan-Systeme
GB9806477D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Improved crystals
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US20040141925A1 (en) 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6725281B1 (en) 1999-06-11 2004-04-20 Microsoft Corporation Synchronization of controlled device state using state table and eventing in data-driven remote device control model
CA2317999C (fr) 1999-09-11 2004-11-09 Glaxo Group Limited Formulation pharmaceutique de propionate de fluticasone
US7037999B2 (en) 2001-03-28 2006-05-02 Texas Petrochemicals Lp Mid-range vinylidene content polyisobutylene polymer product and process for producing the same
GB9925934D0 (en) 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
ES2238334T3 (es) 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
US20070087637A1 (en) 2004-10-15 2007-04-19 Zart Bryan J Connector assembly for an implantable medical device and process for making
GB0016040D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0015981D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
WO2005049357A2 (fr) 2003-11-18 2005-06-02 The Braun Corporation Systeme de commande electronique et procede de systeme de securite de verrouillage de dispositif auxiliaire
GB0023653D0 (en) 2000-09-27 2000-11-08 Cambridge Consultants Device for dispensing particulate material
US7055721B2 (en) 2001-03-23 2006-06-06 Chong Woo Co., Ltd. Finger-operated spray pump ejaculating fluid in fixed quantity
US20030003263A1 (en) 2001-06-06 2003-01-02 Smith Ronald L. Kit for making decorative articles
US7840634B2 (en) 2001-06-26 2010-11-23 Eastman Kodak Company System and method for managing images over a communication network
JP4200348B2 (ja) 2001-07-06 2008-12-24 日本電気株式会社 移動体端末及びその着信鳴動方法
US6955905B2 (en) 2001-07-18 2005-10-18 The Burnham Institute PR/SET-domain containing nucleic acids, polypeptides, antibodies and methods of use
GB0125604D0 (en) 2001-10-25 2001-12-19 Glaxo Group Ltd Novel process
GB0201400D0 (en) 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
GB0202564D0 (en) 2002-02-04 2002-03-20 Glaxo Group Ltd Process
JP3979113B2 (ja) 2002-02-12 2007-09-19 セイコーエプソン株式会社 チャンバ装置の大気置換方法、チャンバ装置、これを備えた電気光学装置および有機el装置
AU2003246829A1 (en) 2002-02-19 2003-09-09 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
GB0208609D0 (en) 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
WO2003088949A2 (fr) 2002-04-19 2003-10-30 Bioghurt Biogarde Gmbh & Co. Kg. Matrice a constituant bioactif contenant des phospholipides
AU2003251303A1 (en) 2002-05-21 2003-12-12 Glaxo Group Limited Pharmaceutical products and methods of manufacture
EP1375517A1 (fr) 2002-06-21 2004-01-02 Smithkline Beecham Corporation Structure du domaine de liaison du ligand du récepteur de glucocorticoides comportant une poche de liaison expansée et procédé d'emploi
US6778145B2 (en) 2002-07-03 2004-08-17 Northrop Grumman Corporation Wideband antenna with tapered surfaces
US7190468B2 (en) 2002-07-17 2007-03-13 Hewlett-Packard Development Company, L.P. Background document rendering system and method
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
US6778740B2 (en) 2002-07-31 2004-08-17 Agilent Technologies, Inc. Alignment of optical fiber elements
US20040020883A1 (en) 2002-08-02 2004-02-05 Brokaw Paul E. Adhesive mounted storage rack, method, and kit
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
WO2004073827A1 (fr) 2003-02-21 2004-09-02 The University Of Bath Procede de production de particules
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
RU2003111926A (ru) * 2003-04-24 2004-10-20 Ципла Лтд. (In) Способ получения флутиказонпропионата
EP1622875B1 (fr) 2003-05-08 2009-12-02 Theravance, Inc. Formes cristallines d'un agoniste arylaniline du récepteur adrénergique bêta-2
US20050009067A1 (en) 2003-05-19 2005-01-13 Craig Logsdon Expression profile of pancreatic cancer
JP4249544B2 (ja) 2003-06-06 2009-04-02 セイコーエプソン株式会社 液晶表示装置、及び電子機器
US20050012360A1 (en) 2003-07-14 2005-01-20 Clark Equipment Company Work vehicle cab screen
GB0318353D0 (en) 2003-08-05 2003-09-10 Phoqus Pharmaceuticals Ltd Coating of surgical devices
EP1526139A1 (fr) 2003-10-24 2005-04-27 S.N.I.F.F. Italia S.P.A. Procédé pour la préparation d'acides 17-beta-carboxyliques d'androstane et d'esters fluorométhylés de l'acide 17-beta-carboxylique d'androstane de haute pureté
WO2005046663A1 (fr) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Composes d'ammonium quaternaire contenant des activateurs de la biodisponibilite
JP2005154815A (ja) 2003-11-21 2005-06-16 Mitsui Mining & Smelting Co Ltd 電解銅箔製造用銅電解液及び電解銅箔の製造方法
BRPI0418386A (pt) 2003-12-31 2007-05-22 Cydex Inc formulação inalante contendo éter sulfoalquìlico gama-ciclodextrina e corticosteróide
US20070020298A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20050192264A1 (en) 2004-02-04 2005-09-01 Penfold Philip L. Slow release steroid composition
US7150432B2 (en) 2004-06-18 2006-12-19 The Boeing Company Horizontal augmented thrust system and method for creating augmented thrust
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
US20060004585A1 (en) 2004-06-30 2006-01-05 Kimberly-Clark Worldwide, Inc. Supplier advisory management system
JP2006017782A (ja) 2004-06-30 2006-01-19 Fuji Photo Film Co Ltd 電子ビーム描画方法
US7375245B2 (en) 2004-07-07 2008-05-20 Everlight Usa, Inc. N-(4-oxo-butanoic acid) -L-amino acid-ester derivatives and methods of preparation thereof
CA2575376A1 (fr) 2004-07-26 2006-02-02 Chemagis Ltd. Nouvelles formes cristallines d'acide 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-propionyloxy-androsta-1,4-diene-17beta-carboxylique et procede de preparation
US20060045850A1 (en) 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
AU2006225117A1 (en) 2005-03-16 2006-09-21 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
AU2006226887A1 (en) 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
US7602077B2 (en) 2005-05-03 2009-10-13 Magenn Power, Inc. Systems and methods for tethered wind turbines
SE528741C2 (sv) 2005-06-20 2007-02-06 Metso Paper Inc Malapparat av skivtyp
US7414623B2 (en) 2005-06-29 2008-08-19 Microsoft Corporation Adaptive sampling for procedural graphics
JP2007011785A (ja) 2005-06-30 2007-01-18 Toshiba Corp 情報処理装置、およびタッチパネルの振動制御方法
JP2007012937A (ja) 2005-06-30 2007-01-18 Seiko Epson Corp 表示ドライバ
US7707786B2 (en) 2005-07-06 2010-05-04 Morgan Theophilus Modular area wall
TWI319160B (en) 2005-07-11 2010-01-01 Via Tech Inc Memory card capable of supporting various voltage supply and control chip and method of supporting voltage thereof
US20100011960A1 (en) 2005-07-18 2010-01-21 Colin Lawrence Electrostatic Air Filter
GB0516148D0 (en) 2005-08-05 2005-09-14 Cavendish Kinetics Ltd Method of integrating an element
US20090082321A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
MX339797B (es) 2005-10-18 2016-06-10 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
JP2009519972A (ja) 2005-12-15 2009-05-21 アキュスフィア, インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
LV13630B (en) 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
AU2007258949B2 (en) 2006-06-14 2013-02-21 Generics [Uk] Limited Process for the preparation of S-fluoromethyl-6, 9 -difluoro-11 -hydroxy-16 -methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17 -carbothioate and intermediates
US20080031219A1 (en) 2006-08-01 2008-02-07 Lucent Technologies, Inc. Accessing an access network to enable grade of service in calls or flow requests for target users of access terminals
US8093896B2 (en) 2006-09-21 2012-01-10 Massachusetts Institute Of Technology Uniform magnetic field spherical coil for MRI
PL2077830T3 (pl) 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
CN100497367C (zh) * 2006-12-19 2009-06-10 高邮市兆康制药有限公司 丙酸氟替卡松的合成方法
EP1936457B1 (fr) 2006-12-20 2009-04-08 Sick Ag Dispositif de couplage de sécurité modulaire et procédé de couplage de sécurité
CA2679448A1 (fr) 2007-02-28 2008-09-04 Aciex, Inc. Procedes et compositions permettant de normaliser les secretions des glandes de meibomius
GB0705159D0 (en) 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
GB0711680D0 (en) 2007-06-18 2007-07-25 Prosonix Ltd Process
ES2493641T3 (es) 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8818272B2 (en) 2007-07-18 2014-08-26 Broadcom Corporation System and method for remotely controlling bluetooth enabled electronic equipment
US7707534B2 (en) 2007-07-25 2010-04-27 Dell Products, Lp Circuit board design tool and methods
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
US7737414B2 (en) 2007-10-26 2010-06-15 Academia Sinica Atomically sharp iridium tip
MX349677B (es) 2007-11-13 2017-08-08 Meritage Pharma Inc Composiciones corticosteroides.
US20090233891A1 (en) 2008-03-11 2009-09-17 Glenmark Generics Ltd. Pharmaceutical lotion comprising fluticasone propionate
WO2009126237A2 (fr) 2008-04-08 2009-10-15 Jamison Will C Cuiseur d'aliment à vapeur
US20100001885A1 (en) 2008-07-03 2010-01-07 Chung-Ping Chi Automatic key function switch device by sensing direction for a handheld apparatus
MX2011000410A (es) 2008-07-18 2011-03-24 Prosonix Ltd Proceso para mejorar la cristalinidad de particulas de fluticasona.
US20100024062A1 (en) 2008-07-24 2010-01-28 Monsanto Technology Llc Soybean variety d5589654
WO2010016931A2 (fr) 2008-08-07 2010-02-11 Plus Chemicals Sa Polymorphes du furoate de fluticasone et leur procédé de préparation
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
JP2010111592A (ja) 2008-11-04 2010-05-20 Aska Pharmaceutical Co Ltd プロピオン酸フルチカゾンを含む局所投与剤
CN101798331A (zh) * 2008-12-25 2010-08-11 国家纳米技术与工程研究院 一种丙酸氟替卡松微细颗粒的制备工艺及其制品
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
PT2408453T (pt) 2009-03-17 2022-04-05 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
JP2010215133A (ja) 2009-03-18 2010-09-30 Central Glass Co Ltd 装飾モールおよび枠体付き車両用窓ガラス
US20100240629A1 (en) 2009-03-19 2010-09-23 Adrienne Kovacsne-Mezei Polymorphs of fluticasone furoate and processes for preparation thereof
WO2010141834A1 (fr) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Formulations ophtalmiques de fluticasone et procédés d'utilisation
KR101541823B1 (ko) 2009-07-02 2015-08-04 알콘 리서치, 리미티드 눈, 귀, 또는 코 감염의 치료를 위한 조성물 및 방법
EP2273405A1 (fr) 2009-07-07 2011-01-12 Irdeto Access B.V. Traitement de contenu enregistrable dans un flux
TW201103350A (en) 2009-07-09 2011-01-16 Ralink Technology Corp Base station selection method for a wireless communication system and device using the same
US8217116B2 (en) 2009-07-15 2012-07-10 Braskem America, Inc. Polypropylene composition for buried structures
US20110022417A1 (en) 2009-07-24 2011-01-27 Rao Nagaraj V Insurance quoting system and method
ES2742525T3 (es) 2009-10-01 2020-02-14 Adare Pharmaceuticals Us L P Composiciones de corticosteroides administradas oralmente
CN102811715A (zh) 2009-12-08 2012-12-05 悉尼大学 可吸入制剂
TR201000681A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
TR201000622A2 (tr) 2010-01-28 2011-08-22 Bi̇lgi̇ç Mahmut Tiotropyum içeren farmasötik kombinasyonlar.
EP2523667A4 (fr) 2010-01-15 2014-04-02 Lithera Inc Préparations pour gâteaux lyophilisés
EP2528600B1 (fr) 2010-01-28 2016-06-29 Mahmut Bilgic Composition pharmaceutique de poudre sèche comprenant le tiotropium et le fluticasone
TR201000685A2 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.
WO2011093811A2 (fr) 2010-01-29 2011-08-04 Mahmut Bilgic Préparations pharmaceutiques comprenant du formotérol et du fluticasone
TR201000733A2 (tr) 2010-02-02 2011-08-22 Bi̇lgi̇ç Mahmut Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
WO2011136753A1 (fr) 2010-04-26 2011-11-03 Mahmut Bilgic Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires
US20130064870A1 (en) * 2010-05-20 2013-03-14 Sun Pharma Advanced Research Company Limited Dry powder inhalation composition
US20120006517A1 (en) 2010-07-08 2012-01-12 Heatron, Inc. Thermally Conductive Sleeve, Heating System, and Method of Use
JP2013536835A (ja) * 2010-09-01 2013-09-26 カディラ・ヘルスケア・リミテッド プロピオン酸/フロ酸フルチカゾンを調製するための方法
ES2626134T3 (es) 2011-01-04 2017-07-24 Bausch & Lomb Incorporated Composiciones de bepotastina
GB201102237D0 (en) 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
AU2012282936B2 (en) 2011-07-08 2016-11-10 Pfizer Limited Process for the preparation of fluticasone propionate form 1

Also Published As

Publication number Publication date
RU2018125932A3 (fr) 2022-01-20
US10954263B2 (en) 2021-03-23
RU2018125932A (ru) 2019-03-12
EP3741772A1 (fr) 2020-11-25
JP2018083846A (ja) 2018-05-31
HK1207087A1 (en) 2016-01-22
CN107880091A (zh) 2018-04-06
JP2015520149A (ja) 2015-07-16
US10174071B2 (en) 2019-01-08
ES2813397T3 (es) 2021-03-23
PT3517541T (pt) 2020-08-28
CA2872845A1 (fr) 2013-11-14
HK1252481A1 (zh) 2019-05-24
PL3517541T3 (pl) 2020-12-28
HUE050993T2 (hu) 2021-01-28
JP2020189877A (ja) 2020-11-26
EP2847207A1 (fr) 2015-03-18
BR112014027681B1 (pt) 2023-02-14
US20190169224A1 (en) 2019-06-06
EP3517541B1 (fr) 2020-07-15
ES2727474T3 (es) 2019-10-16
AU2013259872A1 (en) 2014-11-27
WO2013169647A1 (fr) 2013-11-14
KR102129426B1 (ko) 2020-07-02
MX361886B (es) 2018-12-18
EP2847207B1 (fr) 2019-03-27
CN107880091B (zh) 2020-12-18
US20210300963A1 (en) 2021-09-30
JP6752940B2 (ja) 2020-09-09
JP2019167382A (ja) 2019-10-03
DK3517541T3 (da) 2020-09-07
CN104350063B (zh) 2018-01-05
KR20150013158A (ko) 2015-02-04
JP6285419B2 (ja) 2018-02-28
RU2014149115A (ru) 2016-06-27
JP6972255B2 (ja) 2021-11-24
BR112014027681A2 (pt) 2017-06-27
EP3517541A1 (fr) 2019-07-31
EP2847207A4 (fr) 2015-11-11
ZA201408119B (en) 2016-08-31
CN104350063A (zh) 2015-02-11
BR112014027681B8 (pt) 2023-10-31
JP6564891B2 (ja) 2019-08-21
MX2014013523A (es) 2015-10-22
RU2663117C2 (ru) 2018-08-01
US11814408B2 (en) 2023-11-14
EP3741772B1 (fr) 2024-06-19
US20180022775A1 (en) 2018-01-25
AU2013259872B2 (en) 2018-06-28
CA2872845C (fr) 2021-11-09

Similar Documents

Publication Publication Date Title
IN2014DN09326A (fr)
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
BR112015024869A2 (pt) administração nasal
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
GB201209613D0 (en) New compounds
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
NZ710726A (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
BR112015028964A2 (pt) composição de suspensão, e, método para tratar uma doença ou um distúrbio pulmonar
WO2014016548A3 (fr) Composition pharmaceutique
WO2014151456A3 (fr) Traitement de maladies inflammatoires
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
HK1197235A1 (zh) 二氫吡唑、其藥物組合物及其治療生育障礙的用途
TR201905319T4 (tr) Nevralji, ağrı, KOAH (Kronik, Obstruktif Akciğer Hastalığı) ve astım tedavisinde TRPM8-inhibitörleri olarak yararlı 2-aril-4-hidroksi-1,3-tiyazol türevleri.
DOP2010000122A (es) Terapia de combinacion
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX362485B (es) Nuevos inhibidores de rock.
IN2014MN02133A (fr)